Table 2.
Health outcomes and healthcare resource utilization in individuals ≥50 YOA (base case)
| No vaccination |
Private market setting (RZV vaccination coverage: 5%) |
Mass vaccination setting (RZV vaccination coverage: 50%) |
||||||
|---|---|---|---|---|---|---|---|---|
| Cases | Cases | Cases avoided | Cases | Cases avoided | ||||
| HZ | 1,654,291 | 1,610,723 | 43,568 | 1,218,610 | 435,681 | |||
| PHN | 249,525 | 244,369 | 5,156 | 197,967 | 51,558 | |||
| HZ-related complications other than PHN | 57,572 | 56,002 | 1,570 | 41,870 | 15,703 | |||
| Ocular | 11,893 | 11,556 | 337 | 8,523 | 3,370 | |||
| Neurological (meningitis) | 3,450 | 3,345 | 105 | 2,403 | 1,048 | |||
| Auricular | 27,744 | 26,993 | 751 | 20,237 | 7,507 | |||
| Other | 14,485 | 14,107 | 378 | 10,706 | 3,779 | |||
| HZ-related deaths |
162 |
160 |
2 |
143 |
19 |
|||
| Healthcare resource utilization | ||||||||
| Hospitalizations | 69,470 | 68,045 | 1,425 | 55,223 | 14,247 | |||
| Outpatient visits | 3,900,829 | 3,797,690 | 103,139 | 2,869,441 | 1,031,387 | |||
HZ: herpes zoster; PHN: postherpetic neuralgia; RZV: recombinant zoster vaccine; YOA: years of age. The total cohort vaccinated was 347,900 in the private market setting and 3,479,000 in the mass vaccination setting analysis. Small discrepancies between subgroups and total cases may be present due to rounding.